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Background: Nutritional compounds can exert both anti-inflammatory and anti-oxidant
effects. Since these events exacerbate the pathophysiology of muscular dystrophies,
we investigated nutraceutical supplementation as an adjuvant therapy in dystrophic
patients, to low costs and easy route of administration. Moreover, this treatment could
represent an alternative therapeutic strategy for dystrophic patients who do not respond
to corticosteroid treatment.
Objective: A 24 weeks randomized double-blind placebo-controlled clinical study was
aimed at evaluating the safety and efficacy of daily oral administration of flavonoids-
and omega3-based natural supplement (FLAVOMEGA) in patients affected by muscular
dystrophy with recognized muscle inflammation.
Design: We screened 60 patients diagnosed for Duchenne (DMD),
Facioscapulohumeral (FSHD), and Limb Girdle Muscular Dystrophy (LGMD). Using
a computer-generated random allocation sequence, we stratified patients in a 2:1:1
ratio (DMD:FSHD:LGMD) to one of two treatment groups: continuous FLAVOMEGA,
continuous placebo. Of 29 patients included, only 24 completed the study: 15 were
given FLAVOMEGA, 14 placebo.
Results: FLAVOMEGA was well tolerated with no reported adverse events.
Significant treatment differences in the change from baseline in 6min walk
distance (6MWD; secondary efficacy endpoint) (P = 0.033) and in isokinetic knee
extension (P = 0.039) (primary efficacy endpoint) were observed in LGMD and
FSHD subjects. Serum CK levels (secondary efficacy endpoint) decreased in all
FLAVOMEGA treated groups with significant difference in DMD subjects (P = 0.039).
Sitzia et al. FLAVOMEGA Supplementation for MDs
Conclusions: Although the small number of patients and the wide range of disease
severity among patients reduced statistical significance, we obtained an optimal profile
of safety and tolerability for the compound, showing valuable data of efficacy in primary
and secondary endpoints.
Trial registration number: NCT03317171
Retrospectively registered 25/10/2017
Keywords: nutraceutical supplementation, Duchenne muscular dystrophy, safety, tolerability, strength recovery
INTRODUCTION
Muscular dystrophies (MDs) are a heterogeneous group of
disorders that lead to muscular weakness and—sometimes—to
premature death: although the causative mutations involve
different muscular proteins, they share similar fibrotic
substitution of degenerated fibers (1) and other secondary
aspects as increased reactive oxygen specie (ROS) formation,
mitochondria perturbations and, more importantly, sustained
inflammation (2). The variability of the clinical phenotype
and disease progression may be only partly attributable to
the genotype. Variable degrees of muscle involvement were
reported in dystrophic patients sharing the same mutation,
suggesting that additional genetic or environmental factors
may be playing a role in modulating the phenotype. Among
the dystrophic features, the muscle infiltration of immune
cell is a hallmark of dystrophies and its severity varies among
genotypes, even among allelic variants of the same genotype,
and among individual patient’s muscles or single biopsy,
and over time within individual patients. As an example, the
rising of inflammation and the consequent activation of the
immune system are evident in Duchenne muscular dystrophy
(DMD) (2, 3) and in many forms of Limb Girdle Muscular
Dystrophies (LGMD) such as dyspherlynopathies (LGMD-2B)
(4) calpainopathy (LGMD-2A), and desminopathy (LGMD-2R)
(5). Similar to DMD, invasion of macrophages and CD4+ T
cells were commonly observed in LGMD biopsies (6). The
active role of inflammatory cues was also demonstrated in
the early muscular damage of facioscapulohumeral muscular
dystrophy (FSHD) (7, 8). Evidence exists for response to
immunomodulating therapies such as corticosteroids in some
of the MDs (9–13) but are associated with many side effects
(13). Future avenues for research include development of new
anti-inflammatory drugs targeting the ROS production and
NF-κB pathway (14–17). Importantly, cause-specific treatments
are currently being investigated in clinical trials to replace the
mutated gene using adeno-associated virus (AAV) vector in
LGMD patients (ClinicalTrials.gov identifiers: NCT03492346
and NCT03652259) (18) and to restore the correct open-reading
frame of dystrophin pre-mRNA in DMD patients (19, 20).
In particular, Eteplirsen (an anti-sense oligonucletide) was
recently approved by the Food and Drug Administration (FDA)
to treat approximately 14% of patients with DMD mutations
that can be restored through specific skipping of exon 51
(21, 22). Similarly, the European Medicines Agency approved
the Ataluren, specifically designed to allow readthrough of
nonsense mutations in DMD patients (23, 24). However,
muscle inflammation represent a hostile and detrimental
environment for the efficacy of these new therapies. Chronic
inflammation increases the bioenergetics metabolic rate and
demand of energy of MD patients (25). Supplements such as
Coenzyme Q10 (CoQ10), carnitine, amino acids (glutamine,
arginine), anti-inflammatory/antioxidants (fish oil, vitamin E,
polyphenols) have been proposed as dietary treatment which
affects the level of metabolites, reduces free radicals, or stimulates
antioxidant enzymes (26–30). Furthermore, supplementation
with curcumin or creatine plus CoQ10 reduces NF–κB activity
and modulates mitochondrial respiratory chain function with
energy production (31). Interestingly, combinatorial therapies
with amino acids plus deflazacort have been proposed in DMD
patients to improve nitrogen retention and maintain protein
balance (32–35). However, since dosage and safety requirements
as stringent as those needed for pharmacological compounds
are not necessary in the field of nutritional interventions,
clinical investigations of supplement diet effects in MDs are
mandatory to determine the most valuable ones. We previously
demonstrated that a combination of flavonoids (curcumin,
baicalin, and green tea) and omega3 as main compounds
ameliorates dystrophic features in the animal model of DMD, the
mdx mouse. This treatment improved endurance and muscular
features by reducing muscle fiber necrosis and fibrosis deposition
and by increasing muscle mass. Although the mechanism of
action is not completely clarified, we demonstrated its scavenger
activity on ROS production and its anti-inflammatory properties
regulating the recruitment of inflammatory cells in muscle
tissues (36). In another work, we showed that mdx supplemented
with specific branched-chain amino acid-enriched mixture
(BCAAem) ameliorated the pathological phenotype (37).
Here we report the results of a single center randomized
double-blind placebo controlled study planned to validate our
preclinical evidences (36) and assess the safety and partially
the efficacy of dietary supplementation of flavonoids- and
omega3-based natural supplement (hereafter referred to as
FLAVOMEGA) in 29 dystrophic patients diagnosed for DMD,
FSHD, and LGMD.
SUBJECTS AND METHODS
Trial Registration: Standard Protocol
Approvals, Registrations, and Patient
Consents
This phase II, randomized double-blind placebo-controlled
clinical study was conducted at the Fondazione IRCCS Ca’
Frontiers in Neurology | www.frontiersin.org 2 July 2019 | Volume 10 | Article 755
Sitzia et al. FLAVOMEGA Supplementation for MDs
TABLE 1 | FLAVOMEGA composition.
Oily phase Ingredient For 100 ml Daily dosage
(stick-pack)
DHA 19.231 g 1,250 mg
EPA 6g 360 mg
Vitamin E 0.554 g 36 mg
Lemon essential oil 0.114 g 7.395 mg
Total 6.5 ml
Powdered
phase
Ingredient For 100 g Daily dosage
(stick-pack)
Curcumin complexed
with phospholipid
20.000 g 1000.000 mg
Acetyl L-Carnitine 15.000 g 750.000 mg
Ascorbic acid 4.800 g 240.000 mg
Coenzyme Q10 4.000 g 200.000 mg
Dry extract of the roots of
scutellaria
2.106 g 105.300 mg
Dry extract of green tea 2.000 g 100.000 mg
Total 5 g
DHA, docosahexaenoic acid; EPA, Eicosapentaenoic acid.
Granda Ospedale Maggiore Policlinico, Milan, Italy. Each
patient (or patient’s parents) gave the written informed
consent for the research. This study was performed in
accordance with International Conference on Harmonisation
of Good Clinical Practice guidelines, the Declaration of
Helsinki (2008) and the European Directive 2001/20/EC. This
monocenter study was approved by the Ethical Committee
at Fondazione IRCCS Ca’ Granda Ospedale Maggiore
Policlinico of Milan, under the acronym PRO1. This trial
was registered on ClinicalTrials.gov with the following
number: NCT03317171.
Data Sharing and Data Accessibility
All data generated or analyzed during this study are included in
this published article (and its Supplementary Information Files)
or available from the corresponding author on
reasonable request.
FLAVOMEGA
UGA Nutraceuticals Srl and Ystem Srl were responsible for
the production and release of placebo and dietary supplement.
FLAVOMEGA and placebo composition are reported in
Tables 1, 2. FLAVOMEGA dose: sachet 1, powdered phase:
80 g net weight per day. Ingredients: fructose, phospholipidic
curcumin, Acetil carnitin-l-HCL, ascorbic acid, flavoring,
CoenzymeQ10, Skullcap (Scutellaria baicalensisGeorgi) Baicalin,
Green Tea (Camellia Sinensis) cathechins, anti-agglomerant:
silicon dioxide, edulcorant: acesulfame potassium and sucralose.
Sachet 2, oily phase: 81.4 g net weight per day, Ingredients:
fish oil 05/25, Vitamin E acetate, citrus (Citrus Limonum)
essential oil.
TABLE 2 | Placebo composition.
Oily phase Ingredient For 100 ml Daily dosage
(stick-pack)
Sunflower oil (Helianthus
annuus L.)
6.436 g
Lemon essential oil 0.064 g
Total 6.5 ml
Powdered
phase
Ingredient For 100 g Daily dosage
(stick-pack)
Fructose 44.600 g 2230.000 mg
Micro-crystalline cellulose 36.000 g 1800.000 mg
β-carotene [E160a(i)] 8.000 g 400.000 mg
Orange flavor 6.000 g 300.000 mg
Cytric acid 4.000 g 200.000 mg
Silicon bioxide (E551) 1.000 g 50.000 mg
Sucralose (E955) 0.400 g 20.000 mg
Total 5 g
Clinical Trial Designation: the
Characteristics of Participants
We designed a phase II, randomized double-blind placebo-
controlled clinical study to assess the safety and efficacy of
one dosing regimen of FLAVOMEGA oral administration in
29 patients affected by DMD, FSHD, and LGMD (Figure 1).
We screened 60 DMD, FSHD, and LGMD patients who were
characterized at the level of their gene mutations and skeletal
muscle biopsy in 6 specialist centers in Italy. Included 29 patients
were evaluated at baseline and after 24 weeks of treatment.
Inclusion criteria featured documented genetic diagnosis and
histological confirmation for inflammatory mononuclear cellular
infiltrates in muscle biopsy of DMD, FSHD, and LGMD patients;
age superior to 9 years for DMD, between 9 and 70 years for
LGMD, and between 20 and 70 years for FSHD; absence of
severe cardiac and pulmonary disease. In particular, we defined
cardiomyopathy with values of left ventricular ejection fraction
(EF) and shortening fraction (SF) of, respectively, <55 or <28%
or both, while severe cardiomyopathy was considered with EF <
45% and SF < 20%. Severe pulmonary disease was determined
by Forced Expiratory Volume in 1 s (FEV1) < 0.8 L and Force
Vital Capacity (FVC) < 40% (38–40). Included DMD patients’
genotyping showed deletion of N-terminal (N = 3), ROD
domain (N = 8), and point mutation of ROD domain (N = 1)
of dystrophin gene. Included LGMD patients’ genotypes were
LGMD-2B (N = 6), LGMD-2A (N = 5), and LGMD-2R (N = 1).
Included FSHD patients presented reduced numbers of repetitive
units of D4Z4 allele <10 (N = 5). Five out 12 LGMD and all
FSHD enrolled patients were males.
Patients treated with corticosteroids for <6 months before
study were not included to avoid bias on FLAVOMEGA
effects and corticosteroid treatment was maintained for
the duration of the study: of screened patients, only four
DMD patients were on corticosteroid with a median
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prednisolone adjusted dose of 11.5 mg/kg/month (range
7.5–24). Steroid dosage was not changed during the study.
None of the subjects had health problems other than muscular
dystrophy. Vital signs such as oxygen saturation, respiratory
frequency, body temperature, and diastolic blood pressure
were normal for age. All included DMD patients were
non-ambulant and no one had severe scoliosis or severe
contractures that could have limited the use the assessment
of strength.
Baseline cardiological examination, ECG and echo showed
right bundle branch block in 5 subjects, minimal mitral valve
insufficiency in 4 subjects, and posterior wall hypertrophy
of no clinical relevance in 6 subjects. Pulmonary function
tests evaluable for 22 subjects were normal in 17 subjects
while 5 subjects had minimal respiratory insufficiency. We
obtained written informed consent from each patient’s parents
or guardians before any study procedure was undertaken; we
obtained written consent from patients when appropriate.
Using a computer-generated random allocation sequence,
we accordingly stratified patients in a 2:1:1 ratio (block size
of six; DMD, FSHD, and LGMD stratification) to one of
two treatment groups: continuous FLAVOMEGA, continuous
placebo. FLAVOMEGA and placebo oral administration had
identical packaging and flavor solutions. Efficacy assessment was
performed by personnel not involved in the general clinical
and safety assessment of patients. Sponsor personnel who did
not have any direct interactions with the investigator site was
unmasked to efficacy and safety data after week 24, when the
database was first locked. However, masking was maintained at
study sites (for patients, their families, investigators, and any
personnel with direct contact with the site) until final database
lock at week 55. Safety and tolerability endpoints included
TABLE 3 | OD patients features at baseline.
Baseline LGMD FSHD
Number 12 5
Age (years ± SD) 48.41 ± 10.73 36.8 ± 9.8
Sex Male 5/12 Male 5/5
Race Caucasian Caucasian
Weight (kg ± SD) 71.66 ± 8.95 72.4 ± 15.32
Walking ability 7/12 5/5
Corticosteroids assumption 0/12 0/5
Years since diagnosis (±SD) 22 ± 7.68 10 ± 7.17
Strength measurement (±SD) 19.42 ± 19.91 100.42 ± 54.52
SD, Standard Deviation.
FIGURE 1 | CONSORT flow diagram.
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adverse event (AEs), serious adverse event (SAEs), laboratory
parameters, and physical examination.
A number of scales exist to evaluate muscle impairment
of MD patients; similarly, different scores are taken in
considerations and widely used for neuromuscular diseases, as
reported in literature (41–44). However, for the prospective
analysis, the functional scores needed to cover the full
spectrum of abilities (i.e., upper and lower limbs). According
to these evidences and considering the proximal weakness as
clinical hallmarks of DMD, FSHD, and LGMD, our clinical
efficacy endpoints included the assessment of endurance by
6MWD (6min walking distance) in walking patients and
dynamometer muscle strength measurement of upper and
lower limbs in both walking and wheelchair patients. The
parent questionnaire data (EK, Egen Klassifikation; ACTIVLIM,
Activity Limitation; ABILHAND, manual ability for adults with
upper limb impairments) scales were also used as previously
described (45–48). During a 24 weeks period, all patients
were administered daily with a dose of either treatment
or placebo, which they independently took in. Two daily
combined sachets, respectively, powdery and oily phase, were
provided for each treatment. Sachets of supplement and placebo
were visually identical. We performed safety and efficacy
assessments at screening baseline and week 24. 6MWD and
dynamometer muscle strength measurements of elbow and knee
flexo/extension were tested as previously described (49, 50).
The 6MWT reflects the physical capacity and walking function
at a submaximal level, evaluates the global and integrated
responses of all the systems involved during exercise, including
the pulmonary and cardiovascular systems and—this way—
it was accepted as a clinically meaningful outcome measure
by the regulatory authorities (51). For the isometric knee
(elbow) extension/flexion, MDs’ patients were seated on Biodex
chair, leg (arm) were positioned with knee (elbow) at 90◦
aligned to dynamometer arm and the isometric tetanic voluntary
contraction of related extensor and flexor muscles were recorded
three times/exercise with 5 s of rest between one cycle and
another. For the isokinetic knee extension/flexion measurement,
during the isokinetic voluntary contraction of leg extensor or
flexor muscles, speed was set and maintained at 20 m/sec. Both
upper and lower limbs were analyzed. EK, ACTIVLIM, and
ABILHAND scales were submitted to all included patients at
baseline and 8, 16, and 24 weeks later as previously described
TABLE 5 | Global strength of all included patients at baseline.
ITT Placebo FLAVOMEGA
Patients (N=) 14 15
Strength measurement Biodex (N/m ± SEM) 18.12 ± 5.72 33.16 ± 13.74
Difference between means 15.04 ± 14.88
95% confidence interval −15.55 to 45.64
t-test (P-value) p = 0.321
PER PROTOCOL
Patients (N=) 12 12
Strength measurement Biodex (N/m ± SEM) 14.75 ± 6.18 37.43 ± 14.84
Difference between means 22.68 ± 16.08
95% confidence interval −10.66 to 56.02
t-test (P-value) 0.172
SEM, Standard error of the mean.
TABLE 4 | Patients features description at baseline.
Baseline DMD OD
ITT Placebo FLAVOMEGA Placebo FLAVOMEGA
Patients (N=) 5 7 9 8
Age (years ± SD) 22.6 ± 2.6 18.43 ± 1.25 44.77 ± 10.23 45.25 ± 13.58
t-test (P-value) P = 0.0039* P = 0.935
Sex Male Male Male 5/9 Male 5/8
Race Caucasian Caucasian Caucasian Caucasian
Weight (kg ± SD) 59.8 ± 7.46 54.43 ± 8.08 67.22 ± 7.69 77.13 ± 11.54
Walking ability 0/5 0/7 8/9 4/8
Strength measurement (Biodex) (N/m ± SD)§ 5.57 ± 1.69 5.89 ± 4.03 21.30 ± 24.30 60.43 ± 63.04
t-test (P-value) P = 0.871 P = 0.107
Corticosteroids assumption 2/5 2/7 0/9 0/8
Year since diagnosis (±SD) 16 ± 3.79 15 ± 2.76 17 ± 6.25 20 ± 11.80
Serum CK (U/L ± SD)** 1051.00 ± 693.17 2402.29 ± 1146.79 627.00 ± 185.03 639.36 ± 642.84
t-test (P-value) P = 0.042* P = 0.956
6MWT (meter walked)** Np Np 313.57 ± 214.19 568.25 ± 130.76
t-test (P-value) Np 0.0617
*statistically significant.
§Mean of global analysis.
**Per Protocol.
ITT, intended to treat population; SD, Standard Deviation.
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(46). Blood analysis were performed at baseline and 24 weeks
later using Sysmex XE-2100 (DASIT), CBC (hemoglobin), and
COBAS analyser (Roche Diagnostic) at Lab Analysis unit,
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico.
Serum levels of β-hydroxybutyrate, free fatty acid (FFA) and
branched-chain amino acids (BCAA) were measured by gas
chromatography-mass spectrometry using the Agilent GCMS
5973Nmass spectrometer system, as described in detail elsewhere
(52). Commercially available kit for ROS detection was used
(Ros-GlowTM H2O2, Promega).
Objectives of the Study
Our primary objectives were to assess the safety and efficacy
of FLAVOMEGA supplementation after 24 weeks of treatment.
The primary endpoints were to verify safety by any significant
changes in blood tests and appearance of side effects and to
verify any significant changes in Biodex System 4 Dynamometer
functional test from baseline to week 24. The secondary efficacy
endpoints were set to verify modifications in 6MWT and CK
concentrations. Exploratory efficacy endpoints included the EK,
ACTIVLIM, and ABILHAND scales (46). Physical examinations
included electrocardiograms (ECGs).
Statistical Considerations
The study was exploratory and not designed or powered to
show a statistically significant difference in the primary and
secondary endpoints between treatment groups. For the primary
and secondary endpoints analysis, we analyzed the data using
linear regression for repeated measures (MMRM) and t test
analysis with Prism Software and SPSS Software, calculating
mean and standard deviation (SD) at baseline in Intended to
treat population (ITT) and adjusted mean for missing value
at baseline and T24 weeks. For each analysis, we indicated
regression coefficient and standard error (SE) and p-value.
95% Confident interval (CI) was considered in each test. For
creatine kinase, linear regression was applied using absolute
difference values (value at T24-value at baseline/value at baseline)
as independent variable to normalize data. For 6MWT, linear
regression was applied using difference in meters walked as
independent variable and treatment and baseline meters walked
were meant as dependent variables. Biodex strength analysis was
conducted normalizing data on baseline value (unpaired t-test)
or by pairing patients at baseline and at T24 weeks (paired t-test).
RESULTS
We screened 60 patients and included 29 patients in accordance
with the study inclusion criteria, from Sept 7, 2015, until January
10, 2016. The final number of patients completing the study
was 24 (Figure 1). At the baseline, the mean (±SD) age for
the total study population was 34.72 ± 15.49 years (range
15–67). Mean ± SD age per disease stratification was 20.17
± 4.78 for DMD (N = 12), 36.80 ± 9.83 for FSHD (N =
5), and 48.42 ± 10.73 for LGMD (N = 12). Demographic
characteristics were much the same across DMD treated group,
while LGMD group had a greater mean age than the other
DMD and FSHD groups, as well as time since first symptoms
and diagnosis (Table 3). Gender difference was present only in
LGMD group, which was composed of 5 males and 7 females
(Table 3). All DMD and 5 LGMD patients were non-ambulant
at baseline, while all FSHD patients were ambulant. 4 LGMD
TABLE 6 | Global strength of DMD and OD included patients at baseline and the values concerning the single Biodex measurement.
DMD OD
Placebo FLAVOMEGA Placebo FLAVOMEGA
Baseline per protocol analysis Mean SD N** Mean SD N P-value Mean SD N Mean SD N P-value
Global strength measurement Biodex (N/m) 5.57 1.69 5 5.89 4.03 7 0.871 21.3 20.73 7 81.58 63.27 5 0.0381*
Isometric knee extension R 5.98 1.11 4 3.78 5.69 7 0.473 39.84 31.26 5 178.61 118.13 5 0.034*
Isometric knee extension L 9.86 7.35 3 6.38 3.53 7 0.322 38.99 34.31 7 146.27 131.07 5 0.061
Isometric knee flexion R 8.59 6.86 3 11.36 7.49 7 0.599 15.44 12.90 7 76.28 51.39 5 0.012*
Isometric knee flexion L 7.25 5.21 2 9.52 5.58 5 0.643 14.50 16.94 7 78.52 42.62 4 0.005*
Isokinetic knee extension R 7.61 3.30 3 9.74 1.93 4 0.326 28.14 27.72 7 104.16 94.21 4 0.069
Isokinetic knee flexion R 9.31 1.63 3 13.22 10.87 4 0.572 19.28 17.42 7 64.67 47.65 4 0.044*
Isokinetic knee extension L 4.68 0.87 3 11.37 0.64 4 0.001* 34.29 33.24 7 119.02 123.17 5 0.182
Isokinetic knee flexion L 5.70 0.80 3 11.76 5.25 4 0.110 22.17 22.58 7 55.41 52.44 5 0.161
Isometric elbow extension R 2.66 0.66 5 3.90 2.72 7 0.347 15.45 13.45 6 29.15 30.69 5 0.346
Isometric elbow extension L 3.89 3.27 5 3.73 2.77 7 0.928 13.95 13.21 7 25.51 28.06 5 0.357
Isometric elbow flexion R 5.20 /§ 1 5.28 0.95 4 /§ 14.20 14.99 7 47.61 31.88 4 0.039*
Isometric elbow flexion L 5.15 /§ 1 2.65 0.07 3 /§ 13.66 16.52 7 39.24 31.65 4 0.105
*Statistically significant.
**N, number of patients that performed the test (observations).
P-value is intended as unpaired t-test P-value.
/§Values are incalculable due to paucity of observations.
SD, Standard Deviation; R, right; L, left.
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TABLE 7 | Linear regression of repeated measure (MMRM) analysis of secondary
endpoints: safety blood test parameters.
AST (U/L) (RV: 29 U/L) Placebo FLAVOMEGA
Patients (N=) 12 13
Mean baseline 41 ± 22.65 51.65 ± 28.35
Mean T 24wk (N=) 39.44 ± 17.78 (9) 41.16 ± 15.90 (8)
Mean difference −1.37 −8.51
P-value (95% CI) 0.651 (−8.239 to 5.489) 0.2901 (−26.10 to 9.076)
ALT (U/L) (RV: 36 U/L)
Patients (N=) 11 14
Mean baseline 57 ± 30.08 68.75 ± 43.34
Mean T 24wk (N=) 46.89 ± 22.21 (8) 57.62 ± 23.78 (9)
Mean difference −6.43 −11.78
P-value (95% CI) 0.2378 (−18.43 to 5.569) 0.2781 (−35.12 to 11.56)
GGT (U/L) (RV: 55 U/L)
Patients (N=) 14 12
Mean baseline 35.14 ± 27.78 22.675 ± 10.71
Mean T 24wk (N=) 33.27 ± 16.15 (11) 23.58 ± 8.80 (9)
Mean difference −3 1.51
P-value (95% CI) 0.6309 (−16.49 to 10.49) 0.4597 (−3.057 to 6.080)
Creatinin (mg/dL) (RV: 0.35–1.2 mg/dL)
Patients (N=) 14 14
Mean baseline 0.37 ± 0.25 0.37 ± 0.31
Mean T 24wk (N=) 0.40 ± 0.23 (8) 0.38 ± 0.32 (7)
Mean difference 0.02 0.007
P-value (95% CI) 0.4015 (−0.025 to 0.055) 0.9226 (−0.165 to 0.179)
Hgb (g/dl) (RV: 11–18 g/dl)
Patients (N=) 14 14
Mean baseline 14.45 ± 1.30 14.65 ± 1.53
Mean T 24wk (N=) 14.31 ± 1.22 (10) 14.83 ± 1.46 (9)
Mean difference 0.11 0.038
P-value (95% CI) 0.6311 (−0.391 to 0.611) 0.8444 (−0.398 to 0.473)
RED cells (×106/µl) (RV: 4.5–6 ×106/µl)
Patients (N=) 13 14
Mean baseline 5.01 ± 0.47 5.06 ± 0.54
Mean T 24wk (N=) 4.90 ± 0.32 (10) 5.06 ± 0.38 (9)
Mean difference 6.26 −2.176
P-value (95% CI) 0.3744 (−8.740 to 21.26) 0.1112 (−5.000 to 0.648)
White cells (×103/µl) (RV: 4.5–11 ×103/µl)
Patients (N=) 14 14
Mean baseline 6.90 ± 1.42 7.60 ± 2.60
Mean T 24wk (N=) 6.12 ± 1.20 (7) 7.89 ± 2.36 (8)
Mean difference −0.36 0.49
P-value (95% CI) 0.1787 (−0.927 to 0.216) 0.2436 (−0.584 to 1.559)
Platelets (×103/µl) (RV: 150–400 ×103/µl)
Patients (N=) 14 14
Mean baseline 250.07 ± 41.50 254.85 ± 64.73
Mean T 24wk (N=) 230.09 ± 47.54 (11) 229.22 ± 42.79 (9)
Mean difference −22.45 −25.25
P-value (95% CI) 0.1073 (−50.73 to 5.826) 0.35 (−84.88 to 34.38)
AST, aspartate aminotransferase; ALT, alanine amino-transferase; GGT, gamma glutamyl
transferase; Hgb, hemoglobin; CI, Confidence Interval.
patients withdrew from the study at different time points during
the 6 months period; 1 FSHD patient did not undergo final
functional tests (Figure 1). Patients’ features before or after group
TABLE 8 | FLAVOMEGA effect at T24 weeks on global strength analysis.
Paired all patients mean global strength Placebo FLAVOMEGA
Mean difference −1.622 −0.553
P-value Wilcoxon Signed rank test *0.0396
N = 24
Paired OD mean global strength
Mean difference −1.907 −0.448
P-value Wilcoxon Signed rank test 0.470
N = 12
Paired DMD mean global strength
Mean difference −1.226 −0.63
P-value Wilcoxon Signed rank test *0.0034
N = 12
*statistically significant.
SEM, Standard error of the mean.
stratification are summarized in Tables 3, 4. Patients’ strength
measurement at baseline after stratification are summarized in
Tables 5, 6 and Supplementary Table 1. No adverse events were
reported. No clinically significant changes from baseline data
were observed on physical examination, in vital signs, or ECGs
(data not shown). No gender-related differences in these values
were found in LGMD patients. No blood test modification was
observed and none of the patients showed liver-enzyme changes
suggesting hepatotoxicity (Table 7). All these data demonstrated
the safety and high-tolerability of FLAVOMEGA in included
dystrophic subjects.
Efficacy of the treatment was analyzed considering all patients
together, without respect to their specific pathology or mutations,
as FLAVOMEGA is thought to exert a broadly active effect on
inflammation and metabolism. Deeper analysis was conducted
separately on DMD group trying to highlight the effectiveness
of treatment on patients gathered with similar biomechanical
features (i.e., low force and loss of ambulation). Similar analysis
was conducted on LGMD and FSHD groups. However, in
these latter cases, considering that randomization did not
account for patients’ mutation and the paucity of subjects, we
could not separately evaluate these groups. This way LGMD
and FSHD patients were considered together and termed as
Other Dystrophies (OD). Nevertheless, both LGMD and FSHD
patients present high intra-group variability in terms of age and
force although they share similar characteristics (still ambulant,
middle-adult age, greater force than DMD group) (Table 3).
Firstly, global strength analysis at T24 weeks (calculated as
the average of each patients’ outcomes) performed considering
all patients belonging to FLAVOMEGA vs. placebo groups
demonstrated a statistically significant effect of treatment in
increasing muscle performance (Wilcoxon test on paired data,
P = 0.0396). This data was confirmed in FLAVOMEGA treated
DMD group (Wilcoxon test on paired data, P = 0.0034) whereas
no significant increase of global strength was observed in
FLAVOMEGA treated OD group (Wilcoxon test on paired data,
P = 0.470) (Table 8).
Similarly, Paired t-test analysis of the quantitative
dynamometer strength measures (calculated as the average
Frontiers in Neurology | www.frontiersin.org 7 July 2019 | Volume 10 | Article 755
Sitzia et al. FLAVOMEGA Supplementation for MDs
of each exercise) demonstrated a stabilization of muscle force
in FLAVOMEGA treated patients while there was a significant
decrease in all placebo patients (mean of differences: −1.84
N/m, P = 0.002) or DMD placebo patients (mean of differences:
−0.89 N/m, P = 0.051), and OD placebo patients (mean of
differences: −2.23 N/m, P = 0.0008) (Table 9 and graph in
Supplementary Figure 1).
DMD patients showed similar strength values as they are
all non-ambulant and of similar age, while a greater variability
was present in OD group as it includes both LGMD and FSHD
patients with different degree of severity of the disease (Table 9
and Supplementary Figure 1). Next, we analyzed whether the
effect of FLAVOMEGA on strength differed between upper and
lower limbs. We evaluated the mean change of force from
baseline by analyzing with unpaired t-test the ratio of quantitative
dynamometer parameter at T24/T-baseline. Although upper-
limbs strength remained unchanged during the study, statistically
significant differences of quantitative dynamometer strength
of lower limbs were found in all treated vs. placebo groups
(P = 0.047). Moreover, statistically significant differences of
quantitative dynamometer strength of lower limbs were also
found in OD treated vs. OD placebo group (P= 0.038) (Table 10
and graph in Supplementary Figure 2).
Dynamometer measurement had some limitations: 8 patients
could not perform the isometric elbow flexion measurement as
their strength was below the lower limit of detection (DMD N
= 2, FSHD N = 4, LGMD N = 2) and 4 patients could not
perform the isokinetic knee flexion/extension measurement as
their strength was below the lower limit of detection (DMD
N = 1, FSHD N = 3). One DMD patient could only perform
the isometric elbow extension measurement. One LGMD patient
did not perform the isometric left knee extension measurement
due to the onset of pain. This way, due to the lower number
of observations, t-test analysis of upper limbs did not reach
statistical significance; similarly, significance is higher in OD
group than in DMD group as almost all OD patients could
perform every test, while 8 DMD patients did not perform at
least 1 measurement. Likewise, the majority of the analysis of
single quantitative muscle strength parameters did not reach
statistical significance due to the low number of observations
(Supplementary Tables 2, 4), except for the isokinetic knee
extension of right leg in OD subjects treated with FLAVOMEGA
(Supplementary Table 3).
6MWT was performed only in OD group as DMD group
include all non-walking patients. We noted a high variability
in 6MWD of OD group in term of total distance walked (100–
700m). Globally, mean of total distance was lower at T-24 weeks
vs. T0 inODplacebo group (mean difference+ SD of total meters
walked T24wk-baseline −6 ± 47.43m), while it was higher at
T-24 weeks vs. T0 in FLAVOMEGA group (mean difference
± SD of total meters walked T24wk-baseline 23.25 ± 59.67).
Linear regression analysis confirmed a significant increase in
meters walked in OD subjects treated with FLAVOMEGA (P =
0.033, regression coefficient+ Standard Error (ES) 78.04± 30.54;
CI 7.61–148.46) vs. placebo group (Table 11). No patients had
accidental fall during 6MWD and all patients completed the test.
No patient lost ambulation during the study.
TABLE 9 | Biodex measurement of strength N/m (paired t-test) considering all
muscular districts before and after treatment (baseline and T24wk) intra
each group.
Strength (N/m) all
muscular district
Paired baseline vs. T24 weeks
All patients Placebo FLAVOMEGA
Mean of differences −1.84 −0.047
SD of differences 5.06 19.64
SEM of differences 0.47 1.839
95% CI −2.78 to −0.90 −3.69 to 3.60
n of pairs 114 114
P-value ***0.0002 0.9798
DMD
Mean of differences −0.89 −0.42
SD of differences 2.52 3.76
SEM of differences 0.44 0.49
95% CI −1.78 to 0.004 −1.39 to 0.55
n of pairs 33 60
P-value 0.051 0.391
OD
Mean of differences −2.23 0.37
SD of differences 5.75 28.39
SEM of differences 0.64 3.86
95% CI −3.50 to −0.96 −7.38 to 8.12
n of pairs 81 54
P-value ***0.0008 0.92
***statistically significant. SD, Standard Deviation; SEM, Standard error of the mean; CI,
Confidence Interval; OD, other dystrophies (FSHD and LGMD).
At week 24, we observed a decrease in serum CK
concentrations for all patients treated with FLAVOMEGA vs.
placebo (mean treatment differences of −670.7 ± 276.3 IU/L;
95% CI −1244 to −97.61; P = 0.0239). Results were confirmed
by linear regression analysis and were statistically significant in
DMD treated vs. DMD placebo group (Table 11 and Figure 2).
Conversely, no statistically significant differences were observed
in OD subjects treated with FLAVOMEGA vs. placebo. Taking
in consideration the significant decrease of CK in non-ambulant
DMD, we compared CK values of non-ambulant OD patients
and found no differences between FLAVOMEGA and placebo
group (coefficient+ SEM:−0.035± 0.412; P-value 95% CI: 0.95;
−0.735± 0.714). No gender-related differences in dynamometer,
6MWT, and CK values were found in LGMD patients.
Results from the parent questionnaire data (EK, ACTIVLIM,
and ABILHAND) showed no statistical differences between
FLAVOMEGA and placebo groups. DMD group showed very
low score in ACTIVLIM scale as expected for age and disease
severity (Table 11).
Finally, we analyzed the serum of treated and untreated
patients to investigate whether the FLAVOMEGA
supplementation could modulate the amount of inflammatory
participants such as ROS and other markers associated to
metabolites such as FFA and BCAA. We found decreased serum
levels of ROS in OD subjects treated with FLAVOMEGA vs.
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TABLE 10 | Biodex measurements of strength as T24wk/baseline ratio and unpaired t-test between Placebo and FLAVOMEGA treated groups.
Strength (T24wk/baseline) All muscular district Lower limbs Upper limbs
All patients Placebo FLAVOMEGA Placebo FLAVOMEGA Placebo FLAVOMEGA
Mean 0.99 ± 0.05 N = 113 1.23 ± 0.14 N = 112 0.91 ± 0.03 N = 75 1.32 ± 0.20 n = 77 1.17 ± 0.12 N = 38 1.04 ± 0.07 N = 35
Mean difference 0.24 ± 0.15 0.41 ± 0.20 −0.12 ± 0.14
95% CI −0.051 to 0.53 0.005 to 0.82 −0.41 to 0.17
Unpaired t-test P-value 0.106 *0.047 0.403
DMD
Mean 0.89 ± 0.06 N = 32 1.23 ± 0.14 N = 57 0.92 ± 0.06 N = 22 1.33 ± 0.21 N = 37 1.15 ± 0.34 N = 11 1.09 ± 0.11 N = 19
Mean difference 0.33 ± 0.19 0.41 ± 0.28 −0.06 ± 0.30
95% CI −0.06 to 0.72 −0.14 to 0.96 −0.67 to 0.55
Unpaired t-test P-value 0.091 0.143 0.838
OD
Mean 1.05 ± 0.05 N = 87 1.01 ± 0.04 N = 49 0.90 ± 0.03 N = 54 1.02 ± 0.05 N = 37 1.09 ± 0.08 N = 25 0.98 ± 0.06 N = 16
Mean difference −0.04 ± 0.07 0.12 ± 0.06 −0.10 ± 0.11
95% CI −0.18 to 0.11 0.007 to 0.24 −0.31 to 0.12
Unpaired t-test P-value 0.619 *0.038 0.367
*statistically significant.
CI, Confidence Interval.
placebo group (P = 0.0295) (Figure 2B). Moreover, serum levels
of ROS increased in DMD treated and placebo groups, suggesting
that oxidative stress was not attenuated by FLAVOMEGA
treatment of DMD subjects (Figure 2B). Conversely, we found a
significantly decreased of circulating levels of valine (P= 0.0463)
and FAA (P = 0.0246) in DMD treated group (Figure 2C)
whereas no differences were found for these biomarkers
between OD treated and placebo group (Figure 2C). Studies of
mitochondrial metabolism in dystrophic tissue have uncovered
significant metabolic perturbations including altered substrate
utilization shifting from long chain fatty acids to carbohydrates
and decreased activity of various enzymes. The greater difference
in valine and FAA in DMD treated group may reflect increase in
energy metabolism.
DISCUSSION
MDs from diverse mutations such as DMD, LGMD and FSHD
can produce an immune response that can amply muscle
pathology (53). Advancing our understanding of the interactions
between the immune system and dystrophic muscle has already
led to identifying new potential immunosuppressant therapeutic
strategies which will may not cure any of the muscular
dystrophies but rather attenuate the severity of the disease
(7, 53–58). Since nutrition is one of the major exogenous
factors modulating different aspects of immune function, we
recently tested the effects of natural polyphenols in dystrophin
deficient animal model and demonstrated the amelioration
of endurance and muscular inflammation and fibrosis (36).
Following these promising evidences, we evaluated the safety
and efficacy of a mix of natural polyphenols (FLAVOMEGA) in
DMD, LGMD, and FSHD patients who were characterized for
their muscle inflammatory background. Our data confirmed the
safety of the FLAVOMEGA treatment since no withdrawals were
recorded from the study because of adverse events. However,
an imbalance in baseline disease severity characteristics was
observed between the DMD and OD (LGMD and FSHD)
arms with inability of DMD to walk and greater mean
age observed in OD group. Moreover, a relatively wide age
range with significant variation in muscle performance was
observed in OD patients between FLAVOMEGA and placebo
groups (Table 4).
These imbalances reflected the inclusion of an older and
more impaired population of DMD and OD patients at baseline.
However, T24 weeks analysis (paired values and MMRM) were
compared to the baseline (1T24) reducing the bias of pre-
existing difference. Interestingly, global dynamometer strength
measurement was statistically increased in all FLAVOMEGA
treated patients and in FLAVOMEGA treated DMD vs.
placebo groups.
6MWD test of OD patients demonstrated no baseline
difference between FLAVOMEGA and placebo groups (Table 4).
Importantly, linear regression analysis of 6MWD changes from
baseline to T24 demonstrated that the FLAVOMEGA treatment
significantly improved the number of meter walked in OD
patients (Table 11).
Additionally, significant improvement on the single
dynamometer strength measurements was observed in
FLAVOMEGA treated OD patients (Tables 6, 10 and
Supplementary Tables 2, 3). Although the significant benefits
in FLAVOMEGA treated OD group might be partially related
to the lower mean baseline of 6MWD values of the placebo OD
group, these data are relevant if we consider the expectations
for a trial of 24 weeks duration performed in LGMD and FSHD
patients with a long-term outcome. Moreover, early stage of
disease and long-term analysis may be more appropriate to
measure therapeutic effect of FLAVOMEGA in LGMD and
FSHD patients.
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TABLE 11 | Linear regression of repeated measure (MMRM) analysis of secondary endpoints: Cpk analysis of absolute variation in serum levels
(T24wk-baseline/baseline), 6MWT analysis of 1T24wk-baseline meters walked, and performance scale analysis of 1T24wk-baseline score.
DMD OD
CpK (U/L) Placebo FLAVOMEGA Placebo FLAVOMEGA
Patients (N=) 5 7 9 6
Mean baseline 1051.00 ± 693.17 2402.29 ± 1146.79 627.00 ± 185.03 639.36 ± 642.84
Mean T 24wk (N=) 1199.40 ± 500.82 (5) 1320.71 ± 711.07 (7) 423.71 ± 206.05 (7) 397.97 ± 214.12 (5)
coefficient + SEM −0.634 0.161 −0.022 0.289
P-value 95% CI 0.003* −0.99 ± -0.270 0.94 −0.665 ± 0.621
6MWT (m)
Patients (N=) Np Np 7 4
Mean baseline Np Np 313.57 ± 214.19 568.25 ± 130.76
Mean T 24 wk (N) Np Np 306.71 ± 180.96 591.5 ± 102.18
coefficient + SEM Np Np 78.04 30.54
P-value 95% CI Np Np 0.033* 7.61 ± 148.47
ACTIVLIM
Patients (N=) 5 7 7 5
Mean baseline 6.2 ± 9.60 2.85 ± 4.33 24.71 ± 7.52 28.2 ± 10.82
Mean T 24 wk (N) 2.6 ± 3.71 3.28 ± 4.85 23.82 ± 7.11 26.8 ± 13.55
coefficient + SEM 2.54 1.41 −1 4.95E-16
P-value 95% CI 0.105 −0.655 ± 5.72 9.06E-135 −1 ± −1
ABILHAND
Patients (N=) 5 7 7 5
Mean baseline 13.8 ± 12.27 15 ± 13.03 33.71 ± 2.36 28.6 ± 11.12
Mean T 24 wk (N) 9.8 ± 9.09 14 ± 11.07 34 ± 1.63 30.6 ± 7.46
coefficient + SEM 3.51 4.47 −0.51 1.75
P-value 95% CI 0.453 −6.600 ± 13.61 0.779 −4.452 ± 3.44
EK
Patients (N=) 5 7 7 5
Mean baseline 16.6 ± 6.8 17 ± 3.91 28 ± 2.08 27.2 ± 4.65
Mean T 24 wk (N) 18 ± 7.31 15.85 ± 5.89 28.42 ± 1.39 28.2 ± 3.03
coefficient + SEM −2.553 2.243 0.281 0.330
P-value 95% CI 0.285 −7.62 ± 2.52 0.417 −0.465 ± 1.027
*statistically significant.
CI, Confidence Interval. coefficient + SEM, Regression coefficient + Standard Error of the Mean.
Serum CK concentration was statistically significant reduced
in DMD patients treated with FLAVOMEGA vs. placebo.
Although in DMD patients CK is known to decrease with
age and stage of the disease, the observed reduction was
irrespective of baseline age and suggests a beneficial role in
reducing muscle necrosis as previously described (59, 60).
No statistically significant differences were observed for the
CK values in FLAVOMEGA treated OD and placebo groups
suggesting that it can be difficult to observe significant CK
modification after a period of 24 weeks in ambulatory LGMD
and FSHD subjects. There were no clinically relevant differences
between treatment groups in clinical chemistry, hematology, or
coagulation values. Dysregulations of BCAA and FAA serum
levels were recently considered as biomarker of muscle disease
in MD subjects (25). Interestingly, we observed the statistically
significant decrease of serum levels of valine and FAA in
DMD group treated with FLAVOMEGA compared to placebo
(Figure 2). These data may suggest an energetic and metabolic
effect of FLAVOMEGA treatment in DMD subjects. In contrast,
serum levels of ROS was similar in OD groups whereas increased
ROS levels were found in FLAVOMEGA and placebo treated
DMD patients suggesting that FLAVOMEGA has not impact
on the oxidative pathways of these patients. Although it seems
that CK, BCAA, and FAA serve as plausible pharmacodynamic
biomarkers for FLAVOMEGA, these data needed validation in
a larger sample sizes of patients with muscular dystrophy. No
statistically significant differences were observed for the EK,
ACTIVLIM, and ABILHAND scales in all tested groups. The
correlation between these scales and disease progression in MDs
is uncertain, so these measures might not be expected to show
any evidence of consistent changes across the study. The study
was exploratory and was not designed to have sufficient power
for any endpoint. We screened a small number of patients
for each category and, therefore, variability in clinical efficacy
endpoints resulted to be quite elevated. Randomization did
not take into account ambulant or non-ambulant patients, or
baseline 6MWD values, which could have affected functional
changes. There were differences in age distribution between
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FIGURE 2 | (A) Ck serum levels in placebo and FLAVOMEGA-treated group as 1T24wk-T baseline. (B) 1T24wk-T baseline of serum levels of ROS in treated and
untreated DMD and OD groups. (C) 1T24wk-T baseline of serum levels β-hydroxybutyrate, FFA, and BCAA in DMD (C) and OD (D) groups. Paired t-test: *P < 0.05.
treated and placebo groups in DMD patients. We bear no
knowledge about other randomized, placebo-controlled clinical
trials testing flavonoids/omega3 supplementation in DMD,
LGMD, and FSHD. A review from the literature retrieved
one study of Pentoxyfillin in DMD patients that failed to
demonstrate strength improvement (61). In contrast, CoQ10
analogs supplementation demonstrated efficacy in phase I/II (62)
and in large phase III studies (63) in improving respiratory
function in DMD subjects. Finally, vitamin C, E, zinc-gluconate
and selenomethionine supplementation showed only partial
benefit in FSHD patients improving maximum voluntary
contraction of quadriceps without affecting 6MWT performance
(64). A summary of nutritional intervention in DMD and
mdx mice by Radley et al., highlighted the potential of
amino acid and protein supplementation in improving muscle
mass and the benefit associated to the use of alternative
medicine such as green-tea extract (65). Our findings suggest
that flavonoids/omega3 supplementation might provide clinical
benefits of patients affected by MDs. Additional trials with large
cohort of MDs patients will offer the opportunity to assess
conclusively the efficacy of flavonoids/omega3 supplementation.
Despite the acknowledged limitations, this study represents a
landmark, being the first controlled diet supplementation study
so far to collect muscle data with 6MWD and dynamometer
tests. Diet supplementation represents a simple and available
treatment, which can be used in combination with other drugs
and may contribute in the maintenance of muscle function,
which is regarded by dystrophic patients and their families as a
meaningful outcome.
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